Structured evidence table for Ginkgo Cognition Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ginkgo Cognition Meta-Analysis | Significant treatment effects of 240 mg EGb 761 daily versus placebo were found for cognition ( p = 0.0467), activities of daily living ( p = 0.0230), and global clinical impression ( p = 0.0371). | 1 | Feng JX (2026) | <i>Ginkgo biloba</i> extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials. |
| Ginkgo Cognition Meta-Analysis | Conclusion The results of our meta-analysis of patients with mild to moderate dementia who had previously had a cerebral infarction verified by neuroimaging showed statistically significant and clinically relevant benefits of EGb 761. | 1 | Feng JX (2026) | <i>Ginkgo biloba</i> extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials. |
| Ginkgo Cognition Meta-Analysis | Introduction Ginkgo biloba leaf extracts belong to the most popular herbal medicines for the treatment of neurological disorders, including Alzheimer's disease (AD) or stroke. | 1 | Feng JX (2026) | <i>Ginkgo biloba</i> extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials. |
| Ginkgo Cognition Meta-Analysis | EGb 761, a proprietary ginkgo leaf extract, has been shown to improve brain cell energy supply, to enhance neurogenesis and neuroplasticity, to decrease blood viscosity and improve brain perfusion. | 1 | Feng JX (2026) | <i>Ginkgo biloba</i> extract EGb 761 in patients with dementia and a history of cerebral infarction-meta-analysis of pooled data from randomised clinical trials. |
| Ginkgo Cognition Meta-Analysis | In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Meta-Analysis | Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Meta-Analysis | Accordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
| Ginkgo Cognition Meta-Analysis | 1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems []. | 3 | Yang YoungSoon (2026) | Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope? |
Source documents